Pakistan’s pharmaceutical sector is experiencing a historic surge, with exports rising 34% in FY25 to $457 million, the highest growth in two decades. The government’s deregulation of non-essential medicines in February 2024 has been a game-changer, allowing companies to adjust prices, invest in production, and eliminate black-market practices.
Expanding Global Footprint
Pakistan’s pharma exports now rank fifth among the country’s fastest-growing export categories, with key markets including:
- Afghanistan (largest importer)
- Philippines, Sri Lanka, Uzbekistan, Iraq, Kenya
- Emerging interest from Vietnam, Myanmar, and Thailand
Innovation and Self-Reliance
The strategy emphasizes:
- Local production of vaccines and APIs to reduce import dependency
- WHO-prequalified facilities for global compliance
- AI-driven drug development and pharmacovigilance
Tackling Illicit Trade
Pakistan faces a $90–100 million annual loss from illicit pharma exports. A proposed Pharma Oversight Council aims to crack down on counterfeit and substandard products.
Vision for 2030
With the global generics market projected to reach $600 billion, Pakistan is positioning itself to serve low-and middle-income countries with high disease burdens. The Pakistan Export Strategy 2023–2027 outlines a roadmap for compliance, innovation, and market access.
+ There are no comments
Add yours